| Name | Title | Contact Details |
|---|
Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.
Scientia Vascular offers access devices (microcatheters / guidewires) and therapies that are optimized to address the evolving needs of interventional specialists. Learn more about our next-generation solutions.
OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.
Pharmaceutical Development Group is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cardioxyl Pharmaceuticals is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.